The addition of valsartan to optimized therapy in a cohort of Japanese patients with coronary heart disease and hypertension provides. Description: RETRACTION: The editors of the European Heart Journal have retracted the article reporting data/results of the Jikei Heart Study. The Lancet has formally retracted the Jikei Heart Study paper, originally published in The retraction had been widely anticipated for more.
|Published (Last):||19 October 2009|
|PDF File Size:||7.90 Mb|
|ePub File Size:||20.85 Mb|
|Price:||Free* [*Free Regsitration Required]|
Given this heatt, we now wish to retract the Jikei Heart Study on the grounds that we no longer have confidence in the published results.
When the Jikei Heart Study was first hheart, Staessen and Richart 2 congratulated the investigators on their report.
But we soon became aware that there was concern in Japan about the trial. In October,we received correspondence expressing concern about the similarity of the standard deviations of the mean blood pressure measurements in the two studies, and we invited the authors to comment.
Lancet retracts Jikei Heart Study of valsartan following investigation
Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns. An investigating committee hsart by Professor Hashimoto from Jikei University was established.
We became aware of this development on April 29,and on May 2 we wrote to Jikei University asking for details of the investigation and requesting that we be kept informed. We wrote again on June 4 and June 19 asking when the investigation might be completed. We wrote again on July 31 after we were made aware that a press conference had been held. The report identifies concern over the reliability of the blood pressure data: The report also comments on the affiliation of the person entrusted with the statistical analysis, Hwart Shirahashi.
Our attempts to obtain a response from Mr Shirahashi were hindered by his recent retirement from Novartis, but the Global Head of Medical Affairs, Dr Usman Azam, did share with The Lancet that Mr Shirahashi had been employed by Novartis throughout the period of the trial and its publication.
Dr Azam also told us: He held the position until Taken together, these findings indicate that there is now sufficient doubt as to the integrity of the Jikei Heart Study and the obfuscation over affiliation of the study statistician for The Lancet formally to retract the paper from the scientific stuy.
Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study: Sum and substance in the Jikei Heart Study. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Eur Heart J ; Concerns about the Jikei Heart Study.
Larry Husten, at Cardiobrief, has been following the story in detail, and notes that the saga began with questions about papers by Hiroaki Matsubarawho now has eight retractions.
Matsubara is not an author on the Jikei study. Another outrageous and potentiall quite dangerous violoation of medical, scientific, and human ethics by Big Pharma trying to sell their products.
There should be some accountability here by executuves at Novartis. If the CNS journals did the right thing, we would have seen several more retractions recently McGill etc.
Of course, The Lancet has been burned before Wakefield… and this is a clinical trial not basic science — hence sanity has prevailed. The Lancet deserves a tip of our hat for such a detailed note. I hope many more journals will take the same detailed approach.
Lancet retracts Jikei Heart Study of valsartan following investigation – Retraction Watch
Learn how your comment data is processed. Leave a Reply Cancel reply Your email address will not be published. Too much skin in the game, as duplications force retraction of psoriasis paper. Papers on potential cancer drugs retracted for image manipulation. Follow Follow this blog Get every new post delivered right to your inbox. Sorry, your blog cannot share posts by email.